Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment
Author(s) -
I. de Nie,
Christel J.M. de Blok,
Tim M. van der Sluis,
Ellis Barbé,
Garry L.S. Pigot,
Chantal M Wiepjes,
Nienke M. Nota,
Norah M. van Mello,
Noelle E Valkenburg,
Judith A.F. Huirne,
Louis Gooren,
R. Jeroen A. van Moorselaar,
Koen M.A. Dreijerink,
Martin den Heijer
Publication year - 2020
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/clinem/dgaa412
Subject(s) - medicine , prostate cancer , androgen deprivation therapy , gynecology , interquartile range , cohort , population , hormone therapy , context (archaeology) , cancer , incidence (geometry) , oncology , cohort study , retrospective cohort study , breast cancer , biology , paleontology , physics , environmental health , optics
Trans women (male sex assigned at birth, female gender identity) mostly use antiandrogens combined with estrogens and can subsequently undergo vaginoplasty including orchiectomy. Because the prostate remains in situ after this procedure, trans women are still at risk for prostate cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom